Company Filing History:
Years Active: 2018-2022
Title: The Innovative Contributions of Catherine Roch
Introduction
Catherine Roch is a prominent inventor based in Allschwil, Switzerland. She has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative drug combinations and treatments. With a total of 2 patents, her work has the potential to impact various medical conditions.
Latest Patents
Catherine Roch's latest patents include a pharmaceutical combination comprising a T-type calcium channel blocker. This invention relates to a combination of a first active ingredient, N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide or a pharmaceutically acceptable salt thereof, and a second active ingredient that has an anti-epileptic effect. Another notable patent involves the use of benzimidazole-proline derivatives, which are compounds designed for the treatment of sundown syndrome. This invention also covers the preparation of such compounds and their pharmaceutically acceptable salts.
Career Highlights
Catherine Roch is currently associated with Idorsia Pharmaceuticals Ltd., where she continues to advance her research and development efforts. Her work is characterized by a commitment to improving patient outcomes through innovative pharmaceutical solutions.
Collaborations
Catherine collaborates with esteemed colleagues, including Christoph Boss and Christine Brotschi, to further enhance the impact of her inventions in the pharmaceutical industry.
Conclusion
Catherine Roch's contributions to pharmaceutical innovation exemplify the vital role of inventors in advancing medical science. Her patents reflect a dedication to addressing complex health challenges through innovative solutions.